Symptomatic versus disease modifying treatments

Mechanistic links between depressive symptoms and cognitive deficits

Validating blood-based biomarker assays for use in Alzheimer’s disease clinical care

Defining subgroups of patients with subjective cognitive decline more likely to progress

European task force recommendations: shifting memory clinics towards prevention

What causes ARIA in response to Alzheimer’s disease immunotherapy?

Assessing depressive symptoms in dementia screening

Distinguishing between disease modifying and symptomatic effects in clinical trials

Relationship between amyloid and tau modulated by astrocyte reactivity

Sex and gender biases in AI

Comparing the performance of blood-based amyloid and tau assays

Phase II trial of AR1001 as a potential treatment for Alzheimer’s disease

Past and future of immunotherapy in Alzheimer’s disease

BBB disruption impacts amyloid biomarker performance

The Women’s Brain Project and how to get involved

Underlying mechanisms of vulnerability in early Alzheimer’s disease